Background Angiomyolipomas are slow-growing tumours associated with constitutive activation
of mammalian target of rapamycin (mTOR), and are common in patients with tuberous …

Purpose: To evaluate the efficacy and safety of atrasentan (ABT-627), an endothelin-A
receptor antagonist, in the treatment of asymptomatic, hormone-refractory prostatic …

Radioembolization with yttrium-90 microspheres ( 90 Y-RE), either glass- or resin-based, is
increasingly applied in patients with unresectable liver malignancies. Clinical results are …

Six families with mosaicism are identified in a series of 62 unrelated families with a mutation
in one of the two tuberous sclerosis complex (TSC) genes, TSC1 or TSC2. In five families, …

Background and purpose: To investigate the prevalence of subependymal giant cell ependymomas
(SEGA) in patients with tuberous sclerosis complex (TSC). Methods: We performed a …

Background The efficacy of radioembolisation for the treatment of liver tumours depends on
the selective distribution of radioactive microspheres to tumorous tissue. The distribution of …

Interactions of imatinib with other drugs have been scarcely reported. We report a previously
unknown effect of imatinib on levothyroxine therapy. Eleven patients (1 with gastrointestinal …

Dihydropyrimidinase (DHP) is the second enzyme in the catabolism of 5-fluorouracil (5FU),
and it has been suggested that patients with a deficiency of this enzyme are at risk from …

Background Mammalian target of rapamycin (mTOR) inhibitors are recommended as first-line
treatment of renal angiomyolipoma associated with tuberous sclerosis complex (TSC) or …

Objectives We examined the long-term effects of everolimus in patients with renal angiomyolipoma
associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. …